High Falls Advisors Inc Takes $205,000 Position in Stryker Co. (NYSE:SYK)

High Falls Advisors Inc bought a new position in Stryker Co. (NYSE:SYK) during the first quarter, according to the company in its most recent filing with the SEC. The firm bought 573 shares of the medical technology company’s stock, valued at approximately $205,000.

A number of other large investors also recently added to or reduced their stakes in the business. Aspen Investment Management Inc raised its position in Stryker by 0.7% in the 1st quarter. Aspen Investment Management Inc now owns 4,368 shares of the medical technology company’s stock worth $1,563,000 after purchasing an additional 31 shares during the period. Harbor Investment Advisory LLC raised its position in Stryker by 0.4% in the 1st quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock worth $2,499,000 after purchasing an additional 31 shares during the period. Proficio Capital Partners LLC raised its position in Stryker by 2.4% in the 1st quarter. Proficio Capital Partners LLC now owns 1,418 shares of the medical technology company’s stock worth $507,000 after purchasing an additional 33 shares during the period. Consolidated Portfolio Review Corp raised its position in Stryker by 3.6% in the 4th quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock worth $294,000 after purchasing an additional 34 shares during the period. Finally, FourThought Financial Partners LLC raised its position in Stryker by 3.3% in the 4th quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock worth $322,000 after purchasing an additional 34 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Shares of NYSE:SYK traded down $3.06 during midday trading on Tuesday, reaching $330.22. 2,352,786 shares of the company were exchanged, compared to its average volume of 1,301,805. The company has a current ratio of 1.71, a quick ratio of 0.99 and a debt-to-equity ratio of 0.56. The business’s fifty day moving average is $339.05 and its two-hundred day moving average is $339.61. Stryker Co. has a one year low of $249.98 and a one year high of $361.41. The stock has a market cap of $125.80 billion, a PE ratio of 37.70, a price-to-earnings-growth ratio of 2.61 and a beta of 0.89.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The firm had revenue of $5.42 billion during the quarter, compared to analyst estimates of $5.40 billion. During the same quarter in the prior year, the business earned $2.54 earnings per share. Stryker’s revenue for the quarter was up 8.5% on a year-over-year basis. As a group, analysts predict that Stryker Co. will post 11.95 earnings per share for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Friday, June 28th will be given a dividend of $0.80 per share. The ex-dividend date is Friday, June 28th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.97%. Stryker’s dividend payout ratio is 36.53%.

Analyst Upgrades and Downgrades

SYK has been the topic of a number of analyst reports. Morgan Stanley lifted their target price on shares of Stryker from $345.00 to $350.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. UBS Group boosted their price objective on shares of Stryker from $339.00 to $351.00 and gave the company a “neutral” rating in a research report on Wednesday, May 1st. Royal Bank of Canada boosted their price objective on shares of Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Stifel Nicolaus boosted their price objective on shares of Stryker from $350.00 to $375.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Finally, Citigroup boosted their price objective on shares of Stryker from $362.00 to $406.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Four equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $372.05.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.